HDACIs and the inhibition of invasive potential

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis Research

Background:

• Cancer cell dissemination is a major challenge in treatment, leading to loco-regional disease and distant metastasis.
• Increased expression of the CXCR4 receptor in tumor cells correlates with poor prognosis and promotes metastatic spread.
• CXCR4 signaling, mediated by its ligand CXCL12, involves pathways like SRC, ERK1/2, and STAT3, which regulate cell migration and apoptosis.

Purpose of the Study:

• To investigate the effect of histone deacetylase inhibitors (HDACIs) on CXCR4 expression and subsequent signaling in tumor cells.
• To determine if HDACI treatment alters the migratory potential of tumor cells in response to CXCL12 stimulation.
• To explore the impact of HDACI-induced changes on key signaling molecules downstream of CXCR4.

Main Methods:

• Treatment of diverse tumor cell types with chemically diverse HDACIs.
• Assessment of CXCR4 receptor expression levels following HDACI treatment.
• Evaluation of CXCL12-induced signaling, including SRC and STAT3 phosphorylation, in HDACI-treated cells.
• Analysis of tumor cell migration in response to HDACI treatment and CXCL12 stimulation.

Main Results:

• HDACI treatment led to increased expression of the CXCR4 receptor across various tumor cell types.
• Despite elevated CXCR4, HDACI-treated cells showed reduced signaling in response to exogenous CXCL12.
• Phosphorylation of SRC and STAT3 at activating sites was diminished, resulting in decreased CXCL12-induced tumor cell migration.
• The study suggests a potential reduction in tumor cell invasiveness due to impaired SRC and STAT3 signaling.

Conclusions:

• HDACIs can upregulate CXCR4 expression in cancer cells.
• HDACIs may counteract the pro-migratory effects of CXCR4 by inhibiting downstream signaling pathways.
• These findings suggest a potential therapeutic strategy where HDACIs could reduce cancer cell metastasis.